Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Cash (2022 - 2025)

Historic Change in Cash for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$61.0 million.

  • Indivior Pharmaceuticals' Change in Cash fell 33571.43% to -$61.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.0 million, marking a year-over-year increase of 14922.6%. This contributed to the annual value of $3.0 million for FY2024, which is 10065.36% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Change in Cash stood at -$61.0 million for Q3 2025, which was down 33571.43% from $136.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Change in Cash peaked at $136.0 million during Q2 2025, and registered a low of -$295.0 million during Q4 2023.
  • Over the past 4 years, Indivior Pharmaceuticals' median Change in Cash value was -$14.0 million (recorded in 2024), while the average stood at -$31.5 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Change in Cash plummeted by 54130.43% in 2023 and then surged by 125000.0% in 2024.
  • Indivior Pharmaceuticals' Change in Cash (Quarter) stood at -$46.0 million in 2022, then tumbled by 541.3% to -$295.0 million in 2023, then skyrocketed by 110.51% to $31.0 million in 2024, then tumbled by 296.77% to -$61.0 million in 2025.
  • Its last three reported values are -$61.0 million in Q3 2025, $136.0 million for Q2 2025, and $53.0 million during Q1 2025.